SYMBYX is an Australian medical technology company developing light (photobiomodulation) therapies and devices for previously intractable, chronic diseases. SYMBYX’s current focus is on managing neurodegenerative conditions such as Parkinson’s and Dementia as well as metabolic diseases including IBD-Crohn’s and Diabetes.
Founded in December 2019 and headquartered in Sydney, Australia, SYMBYX works with a global network of research scientists and has offices and experienced clinicians in Australia, England, Scotland, Germany and Portugal. All of our devices are manufactured in Sweden and Australia and are CE marked and ARTG listed. We are ISO 13485 certified and are in discussions with Health Canada regarding MDSAP approval and with the US FDA for 510K clearance. There are ongoing clinical trials using SYMBYX devices in Australia, US, Canada, Italy and Czech Republic.
SYMBYX designs and develop innovative medical lasers and light devices that are non-invasive, painless to use and portable – mostly for the home or consumer market. (Our Pro-Series Laser is primarily sold to and used by allied health professionals in a clinical setting). All of our devices and protocols are backed by extensive scientific research and over 20 years of combined clinical practice. SYMBYX products are available to purchase worldwide via this website, as well as from a network of SYMBYX-approved clinicians.
In our Parkinson’s work, we primarily treat the gut microbiome, which comprises billions of microscopic organisms such as bacteria, viruses and fungi. By placing the laser directly onto the bare skin of the abdomen, we can access the Gut-Brain-Axis and stimulate the body’s own immune response as well as the production of dopamine (critical for our PDCare Laser and people living with Parkinson’s). There is high-quality, peer reviewed research establishing a close relationship between the brain and the gut and this close relationship is increasingly critical to understanding and learning how to solve many chronic diseases.
Photobiomodulation or light energy from SYMBYX devices works also by stimulating the production of ATP within each targeted cell. ATP or Adenosine triphosphate, is the molecule that carries energy within cells.
As a leader in photobiomodulation and photobiomodulation for Parkinson’s, SYMBYX collaborates with large universities, hospitals, support and advocacy groups and leading international medical professionals in neurology, movement disorders, and general neuroscience. Research results using SYMBYX devices, as well as our company background has been featured in many leading newspapers and media.
We are a team of dedicated and informed health professionals passionate about the healing benefits and power of low-level light. We strive to produce excellent results for our patients and business partners in all that we do.
CEO Wayne Markman discusses our commitment to making a real difference in our customer's lives by providing research based medical devices that are non invasive, painless and drug free.
For further updates about light therapy, SYMBYX clinical trials and new products, please subscribe via our website to our newsletter, and connect with us on social media. Please also email us anytime at email@example.com.